Our Study

The MOMENTUM study is evaluating an investigational therapy (given only one time) that allows the body to produce fetal hemoglobin.

  • Current treatment options for sickle cell disease have limitations: they may not work for everyone and need to be taken forever to maintain benefits.
  • The MOMENTUM study is evaluating an investigational therapy (given only one time) that allows the body to produce fetal hemoglobin.
  • Fetal hemoglobin is an “anti-sickling” hemoglobin that is present in the red blood cells before birth; however, most people stop producing it shortly after birth, which causes it to lose its “anti-sickling” effect.
  • Higher levels of fetal hemoglobin are known to reduce the vaso-occlusive crises that can cause acute pain episodes in people with sickle cell disease.
  • The purpose of this study is to see if this one-time investigational drug is a safe and effective way to reduce or eliminate vaso-occlusive crises in sickle cell disease.

Our Study

About the Investigational Drug

  • This investigational drug is called ARU-1801.
  • ARU-1801 is designed to add a new fetal hemoglobin-generating gene into a person’s own blood-making stem cells. 
  • The new gene is intended to transform those cells and to allow them to make more fetal hemoglobin.
  • If more fetal hemoglobin is made, there may be less sickle–shaped red blood cells. This could lead to less red blood cell clumping and help ease other symptoms of SCD.

Our Study

A Phase 1/2 Trial Investigating ARU-1801 in Adults with SCD

  • The MOMENTUM study is a Phase 1/2 trial that will assess the safety and efficacy of ARU-1801 in adults (age 18 to 45) with SCD.
  • Momentum has already started treating patients with ARU-1801.
  • All eligible participants who complete preparation will receive ARU-1801.
  • The study requires only one administration of ARU-1801.
  • ARU-1801 is designed to permanently add an extra fetal hemoglobin gene into a person’s blood-making stem cells. The goal is to increase production of fetal hemoglobin and reduce the sickle–shaped adult hemoglobin in red blood cells. This could lead to less red blood cell clumping and help ease other symptoms of SCD.

Our Study

Who can Participate?

Have severe SCD as defined by having had one of the following:

  • Two or more painful crises requiring treatment at a medical facility in your life, or
  • Two or more episodes of acute chest syndrome in your life, or
  • One episode of life-threatening acute chest syndrome in your life, or
  • On chronic transfusion therapy for disease symptoms.

Our Study

Key MOMENTUM Information

  • Researchers are examining the safety and efficacy of a one-time investigational drug that is designed to be curative.
  • All participants receive access to investigational drug.
  • Participants are paid for their time and reimbursed for travel to take part in this study.
  • All research procedures will be covered by the study.

What are the benefits and risks?

Benefits:

  • You will be able to try an investigational new therapy that might help you reduce your SCD symptoms.
  • You will have access to this experimental therapy before it is otherwise available.

Risks:

  • The experimental therapy may or may not help your symptoms, but what we learn may help other people with SCD.

The full detailed risks and potential benefits of this trial will be reviewed with you by the study team and investigator, for you to make an informed decision about whether to participate.